Burrows FJ - Search Results

1

Therapeutic and diagnostic implications of Hsp90 activation.

Kamal A, Boehm MF, Burrows FJ. Kamal A, et al. Among authors: burrows fj. Trends Mol Med. 2004 Jun;10(6):283-90. doi: 10.1016/j.molmed.2004.04.006. Trends Mol Med. 2004. PMID: 15177193 Free PMC article. Review.

2

Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors.

Saif MW, Erlichman C, Dragovich T, Mendelson D, Toft D, Burrows F, Storgard C, Von Hoff D. Saif MW, et al. Cancer Chemother Pharmacol. 2013 May;71(5):1345-55. doi: 10.1007/s00280-013-2134-9. Epub 2013 Apr 6. Cancer Chemother Pharmacol. 2013. PMID: 23564374 Clinical Trial.

3

Hsp90 inhibitors as selective anticancer drugs.

Kamal A, Burrows FJ. Kamal A, et al. Among authors: burrows fj. Discov Med. 2004 Oct;4(23):277-80. Discov Med. 2004. PMID: 20704959

4

Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.

Kasibhatla SR, Hong K, Biamonte MA, Busch DJ, Karjian PL, Sensintaffar JL, Kamal A, Lough RE, Brekken J, Lundgren K, Grecko R, Timony GA, Ran Y, Mansfield R, Fritz LC, Ulm E, Burrows FJ, Boehm MF. Kasibhatla SR, et al. Among authors: burrows fj. J Med Chem. 2007 Jun 14;50(12):2767-78. doi: 10.1021/jm050752+. Epub 2007 May 8. J Med Chem. 2007. PMID: 17488003

5

7'-substituted benzothiazolothio- and pyridinothiazolothio-purines as potent heat shock protein 90 inhibitors.

Zhang L, Fan J, Vu K, Hong K, Le Brazidec JY, Shi J, Biamonte M, Busch DJ, Lough RE, Grecko R, Ran Y, Sensintaffar JL, Kamal A, Lundgren K, Burrows FJ, Mansfield R, Timony GA, Ulm EH, Kasibhatla SR, Boehm MF. Zhang L, et al. Among authors: burrows fj. J Med Chem. 2006 Aug 24;49(17):5352-62. doi: 10.1021/jm051146h. J Med Chem. 2006. PMID: 16913725

6

Orally active purine-based inhibitors of the heat shock protein 90.

Biamonte MA, Shi J, Hong K, Hurst DC, Zhang L, Fan J, Busch DJ, Karjian PL, Maldonado AA, Sensintaffar JL, Yang YC, Kamal A, Lough RE, Lundgren K, Burrows FJ, Timony GA, Boehm MF, Kasibhatla SR. Biamonte MA, et al. Among authors: burrows fj. J Med Chem. 2006 Jan 26;49(2):817-28. doi: 10.1021/jm0503087. J Med Chem. 2006. PMID: 16420067

7

ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia.

Castro JE, Prada CE, Loria O, Kamal A, Chen L, Burrows FJ, Kipps TJ. Castro JE, et al. Among authors: burrows fj. Blood. 2005 Oct 1;106(7):2506-12. doi: 10.1182/blood-2005-03-1099. Epub 2005 Jun 21. Blood. 2005. PMID: 15972449 Free PMC article.

8

A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors.

Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, Burrows FJ. Kamal A, et al. Among authors: burrows fj. Nature. 2003 Sep 25;425(6956):407-10. doi: 10.1038/nature01913. Nature. 2003. PMID: 14508491

9

Inhibition of neuroblastoma xenograft growth by Hsp90 inhibitors.

Kang J, Kamal A, Burrows FJ, Evers BM, Chung DH. Kang J, et al. Among authors: burrows fj. Anticancer Res. 2006 May-Jun;26(3A):1903-8. Anticancer Res. 2006. PMID: 16827123 Free PMC article.

10

BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90.

Lundgren K, Zhang H, Brekken J, Huser N, Powell RE, Timple N, Busch DJ, Neely L, Sensintaffar JL, Yang YC, McKenzie A, Friedman J, Scannevin R, Kamal A, Hong K, Kasibhatla SR, Boehm MF, Burrows FJ. Lundgren K, et al. Among authors: burrows fj. Mol Cancer Ther. 2009 Apr;8(4):921-9. doi: 10.1158/1535-7163.MCT-08-0758. Mol Cancer Ther. 2009. PMID: 19372565

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results